About 70% of the MDM2/MDMX co-amplified CRPC tumor samples retain wild-type p53, suggesting that dysregulation of only one of the inhibitors is not sufficient to inactivate p53 for prostate cancer development. Here, MDM4 is linked to prostate carcinoma.